Yuhan Corporation (000105.KS)
KRW 101900.0
(-3.04%)
KRW 101900.0
(-3.04%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -69.18 Billion KRW | 65.0% |
| 2022 | -197.66 Billion KRW | -53.44% |
| 2021 | -128.82 Billion KRW | 44.09% |
| 2020 | -230.4 Billion KRW | -26.08% |
| 2019 | -182.73 Billion KRW | -48.92% |
| 2018 | -122.71 Billion KRW | 0.06% |
| 2017 | -122.78 Billion KRW | -154.45% |
| 2016 | -48.25 Billion KRW | 31.27% |
| 2015 | -70.2 Billion KRW | 17.87% |
| 2014 | -85.48 Billion KRW | 60.76% |
| 2013 | -217.85 Billion KRW | -16.56% |
| 2012 | -186.9 Billion KRW | -10.04% |
| 2011 | -169.85 Billion KRW | -20.4% |
| 2010 | -141.07 Billion KRW | 40.95% |
| 2009 | -238.89 Billion KRW | -78.62% |
| 2008 | -133.74 Billion KRW | -157.47% |
| 2007 | -51.94 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -17.47 Billion KRW | -159.28% |
| 2024 Q1 | 29.47 Billion KRW | 0.0% |
| 2023 Q4 | - KRW | 100.0% |
| 2023 Q2 | -139.14 Billion KRW | 36.92% |
| 2023 Q1 | -220.59 Billion KRW | -11.6% |
| 2023 FY | -69.18 Billion KRW | 65.0% |
| 2023 Q3 | -112.97 Billion KRW | 18.81% |
| 2022 Q4 | -197.66 Billion KRW | -75.42% |
| 2022 Q2 | -86.67 Billion KRW | 7.16% |
| 2022 Q3 | -112.68 Billion KRW | -30.0% |
| 2022 Q1 | -93.35 Billion KRW | 27.53% |
| 2022 FY | -197.66 Billion KRW | -53.44% |
| 2021 Q3 | -80.43 Billion KRW | -53.39% |
| 2021 FY | -128.82 Billion KRW | 44.09% |
| 2021 Q1 | -352.93 Billion KRW | -53.18% |
| 2021 Q4 | -128.82 Billion KRW | -60.16% |
| 2021 Q2 | -52.43 Billion KRW | 85.14% |
| 2020 Q3 | -328.79 Billion KRW | 28.33% |
| 2020 Q1 | -414.58 Billion KRW | -126.87% |
| 2020 Q2 | -458.78 Billion KRW | -10.66% |
| 2020 Q4 | -230.4 Billion KRW | 29.93% |
| 2020 FY | -230.4 Billion KRW | -26.08% |
| 2019 Q3 | -161.92 Billion KRW | -70.16% |
| 2019 Q1 | -146.81 Billion KRW | -19.65% |
| 2019 Q4 | -182.73 Billion KRW | -12.85% |
| 2019 FY | -182.73 Billion KRW | -48.92% |
| 2019 Q2 | -95.15 Billion KRW | 35.19% |
| 2018 Q3 | -119.99 Billion KRW | -5.47% |
| 2018 FY | -122.71 Billion KRW | 0.06% |
| 2018 Q1 | -101.3 Billion KRW | 17.49% |
| 2018 Q2 | -113.76 Billion KRW | -12.3% |
| 2018 Q4 | -122.71 Billion KRW | -2.26% |
| 2017 Q4 | -122.78 Billion KRW | -26.85% |
| 2017 FY | -122.78 Billion KRW | -154.45% |
| 2017 Q1 | -104.2 Billion KRW | -115.94% |
| 2017 Q2 | -115.14 Billion KRW | -10.5% |
| 2017 Q3 | -96.79 Billion KRW | 15.94% |
| 2016 FY | -48.25 Billion KRW | 31.27% |
| 2016 Q4 | -48.25 Billion KRW | 40.62% |
| 2016 Q3 | -81.26 Billion KRW | -2.74% |
| 2016 Q2 | -79.09 Billion KRW | -206.28% |
| 2016 Q1 | -25.82 Billion KRW | 63.21% |
| 2015 Q3 | -93.69 Billion KRW | 23.07% |
| 2015 Q2 | -121.79 Billion KRW | -10.31% |
| 2015 FY | -70.2 Billion KRW | 17.87% |
| 2015 Q1 | -110.4 Billion KRW | -29.16% |
| 2015 Q4 | -70.2 Billion KRW | 25.07% |
| 2014 Q3 | -115.94 Billion KRW | -22.45% |
| 2014 FY | -85.48 Billion KRW | 60.76% |
| 2014 Q1 | -208.24 Billion KRW | 4.41% |
| 2014 Q2 | -94.68 Billion KRW | 54.53% |
| 2014 Q4 | -85.48 Billion KRW | 26.27% |
| 2013 Q4 | -217.85 Billion KRW | -6.75% |
| 2013 Q1 | -209.33 Billion KRW | -12.0% |
| 2013 FY | -217.85 Billion KRW | -16.56% |
| 2013 Q2 | -206.91 Billion KRW | 1.16% |
| 2013 Q3 | -204.06 Billion KRW | 1.37% |
| 2012 Q1 | -198.96 Billion KRW | 0.0% |
| 2012 FY | -186.9 Billion KRW | -10.04% |
| 2012 Q4 | -186.9 Billion KRW | -11.33% |
| 2012 Q3 | -167.88 Billion KRW | 20.11% |
| 2012 Q2 | -210.15 Billion KRW | -5.63% |
| 2011 Q1 | -89.42 Billion KRW | 32.96% |
| 2011 Q2 | -178.53 Billion KRW | -99.65% |
| 2011 FY | -169.85 Billion KRW | -20.4% |
| 2011 Q3 | -182.66 Billion KRW | -2.31% |
| 2010 Q4 | -133.38 Billion KRW | 22.93% |
| 2010 Q1 | -209.47 Billion KRW | 7.61% |
| 2010 Q2 | -222.28 Billion KRW | -6.12% |
| 2010 FY | -141.07 Billion KRW | 40.95% |
| 2010 Q3 | -173.05 Billion KRW | 22.15% |
| 2009 Q2 | -232.13 Billion KRW | -48.86% |
| 2009 Q1 | -155.94 Billion KRW | -18.65% |
| 2009 FY | -238.89 Billion KRW | -78.62% |
| 2009 Q4 | -226.72 Billion KRW | 4.62% |
| 2009 Q3 | -237.72 Billion KRW | -2.41% |
| 2008 Q1 | -102.81 Billion KRW | -92.14% |
| 2008 Q3 | -163.27 Billion KRW | -3.07% |
| 2008 FY | -133.74 Billion KRW | -157.47% |
| 2008 Q4 | -131.43 Billion KRW | 19.5% |
| 2008 Q2 | -158.41 Billion KRW | -54.08% |
| 2007 Q3 | -70.06 Billion KRW | -23.31% |
| 2007 Q1 | -45.73 Billion KRW | 0.0% |
| 2007 Q2 | -56.81 Billion KRW | -24.23% |
| 2007 FY | -51.94 Billion KRW | 0.0% |
| 2007 Q4 | -53.5 Billion KRW | 23.63% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 886.009% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 112.095% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 122.256% |
| HANDOK Inc. | 283.45 Billion KRW | 124.408% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | 444.688% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 135.672% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | -1777.101% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 113.359% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | -113.328% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 191.426% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 287.816% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 183.842% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | 375.551% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 886.009% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 56.717% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 134.43% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 140.473% |
| JW Holdings Corporation | 480.68 Billion KRW | 114.393% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 142.038% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | 58966.337% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 144.818% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 3042.453% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | 400.792% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 139.541% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 233.116% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 886.009% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 143.707% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 119.316% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 144.818% |
| Yuhan Corporation | -69.18 Billion KRW | -0.0% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 150.876% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 215.94% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 116.122% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 144.818% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 159.522% |
| Korea United Pharm Inc. | 16.42 Billion KRW | 521.224% |
| CKD Bio Corp. | 143.29 Billion KRW | 148.282% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 159.609% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | -187.538% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | -54.662% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 3042.453% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 116.362% |
| Boryung Corporation | 187.72 Billion KRW | 136.855% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 3.694% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 191.426% |
| JW Lifescience Corporation | 26.09 Billion KRW | 365.177% |